Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.49 |
| ▸ | PPARD | Q03181 | 8/20 | 0.49 |
| ▸ | PPARA | Q07869 | 8/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023743 | 0.96 | PPARG (0.49) | PPARGPPARDPPARAMCL1TRPV1 | |
| SCHEMBL5016882 | 0.92 | PPARD (0.45) | PPARGPPARDPPARAMCL1TRPV1 | |
| SCHEMBL5016851 | 0.91 | PPARD (0.49) | PPARGPPARDPPARAMCL1 | |
| SCHEMBL5022805 | 0.90 | MCL1 (0.44) | PPARGPPARDPPARAMCL1TRPV1 | |
| SCHEMBL5023328 | 0.88 | PPARG (0.48) | PPARGPPARDPPARAMCL1TRPV1 | |
| SCHEMBL5022823 | 0.87 | PPARD (0.50) | PPARGPPARDPPARAMCL1 | |
| SCHEMBL5016774 | 0.86 | MCL1 (0.45) | PPARGPPARDPPARAMCL1TRPV1 | |
| SCHEMBL5023263 | 0.85 | PPARD (0.54) | PPARGPPARDPPARATRPV1 | |
| SCHEMBL5016845 | 0.84 | PPARD (0.57) | PPARGPPARDPPARA | |
| SCHEMBL5023230 | 0.83 | PPARD (0.55) | PPARGPPARDPPARAMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | claimed |
| US-7265149-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | claimed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | claimed |
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7265149-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203160-A1 | Indolyl derivatives | PPARD, PPARA, PPARG | PPARG 3/4885PPARD 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.